Marinus Pharmaceuticals Inc Quick Ratio (MRNS) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Marinus Pharmaceuticals Inc   (NASDAQ: MRNS)

Marinus Pharmaceuticals Inc 's Quick Ratio

MRNS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2024, Quick Ratio deteriorated to 1.35 a new company low.

Within Major Pharmaceutical Preparations industry 349 other companies have achieved higher Quick Ratio than Marinus Pharmaceuticals Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 803 to 1571.

Explain Quick Ratio?
How much Cash & cash equivalents MRNS´s has?
What are MRNS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRNS Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3
Y / Y Current Liabilities Change 9.38 % 37.31 % 99.31 % 53.55 % 36.12 %
Y / Y Cash & cash equivalent Change -76.08 % -63.11 % -43.15 % 12.07 % 4.82 %
Quick Ratio MRQ 1.35 1.96 2.81 7.02 6.15
MRNS's Total Ranking # 1571 # 803 # 413 # 545 #
Seq. Current Liabilities Change -5.08 % -17.96 % 4.77 % 34.06 % 19.16 %
Seq. Cash & cash equivalent Change -34.78 % -42.89 % -57.99 % 52.87 % 0.58 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 350
Healthcare Sector # 623
Overall Market # 1571


Quick Ratio Statistics
High Average Low
35.27 9.04 1.35
(Sep 30 2014)   (Sep 30 2024)




Financial Statements
Marinus Pharmaceuticals Inc 's Current Liabilities $ 31 Millions Visit MRNS's Balance sheet
Marinus Pharmaceuticals Inc 's Cash & cash equivalent $ 42 Millions Visit MRNS's Balance sheet
Source of MRNS's Sales Visit MRNS's Sales by Geography


Cumulative Marinus Pharmaceuticals Inc 's Quick Ratio

MRNS's Quick Ratio for the trailling 12 Months

MRNS Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 46.07 % 55.39 % 46.99 % 25.47 % 17.92 %
Y / Y Cash & cash equivalent TTM Growth -38.13 % -20.36 % 4.88 % 30.77 % 55.24 %
Quick Ratio TTM 3.42 4.45 5.59 7.37 8.08
Total Ranking TTM # 3502 # 3149 # 1579 # 3062 #
Seq. Current Liabilities TTM Growth 1.91 % 6.83 % 18.02 % 13.68 % 8.42 %
Seq. Cash & cash equivalent TTM Growth -21.51 % -15.07 % -10.48 % 3.67 % 1.03 %

Quick ratio ranking by company, industry and sector >> Back to MRNS Financial Strength Comparisons >> Go to Compare MRNS Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2024 to $31.34 millions, cumulative Quick Ratio decreased to 3.42 below the Marinus Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 461 other companies have achieved higher Quick Ratio than Marinus Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3149 to 3502.

Explain Quick Ratio?
How much Cash & cash equivalents MRNS´s has?
What are MRNS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 462
Healthcare Sector # 939
Within the Market # 3502


trailing twelve months Quick Ratio Statistics
High Average Low
13.18 7.06 2.93
(Dec 31 2014)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Neuphoria Therapeutics Inc   3.65 $ 5.604  Millions$ 1.535  Millions
Nektar Therapeutics  3.62 $ 244.495  Millions$ 67.583  Millions
Inovio Pharmaceuticals Inc   3.61 $ 84.805  Millions$ 23.499  Millions
Insmed Inc  3.59 $ 1,467.908  Millions$ 408.733  Millions
Theriva Biologics inc   3.59 $ 16.409  Millions$ 4.575  Millions
Axsome Therapeutics Inc   3.55 $ 327.341  Millions$ 92.244  Millions
Crescent Biopharma Inc   3.54 $ 14.392  Millions$ 4.060  Millions
Shattuck Labs Inc   3.53 $ 43.829  Millions$ 12.401  Millions
Schrodinger Inc   3.50 $ 388.679  Millions$ 111.117  Millions
Mannkind Corporation  3.49 $ 251.588  Millions$ 72.101  Millions
Urogen Pharma Ltd   3.48 $ 125.155  Millions$ 35.987  Millions
Indaptus Therapeutics Inc   3.47 $ 7.381  Millions$ 2.129  Millions
Arcturus Therapeutics Holdings Inc   3.41 $ 237.178  Millions$ 69.463  Millions
Unity Biotechnology Inc   3.31 $ 29.037  Millions$ 8.784  Millions
Geovax Labs Inc   3.29 $ 8.593  Millions$ 2.608  Millions
Alzamend Neuro Inc   3.26 $ 4.093  Millions$ 1.255  Millions
Gain Therapeutics inc  3.25 $ 12.050  Millions$ 3.708  Millions
Regeneron Pharmaceuticals Inc   3.23 $ 9,796.500  Millions$ 3,033.800  Millions
Nextcure Inc   3.19 $ 27.702  Millions$ 8.672  Millions
Biomea Fusion Inc   3.19 $ 87.952  Millions$ 27.572  Millions
Ibio inc   3.19 $ 11.064  Millions$ 3.469  Millions
Rein Therapeutics Inc   3.12 $ 17.652  Millions$ 5.659  Millions
Mineralys Therapeutics Inc   3.11 $ 97.274  Millions$ 31.321  Millions
Annovis Bio Inc   3.08 $ 12.637  Millions$ 4.099  Millions
Rhythm Pharmaceuticals Inc   3.06 $ 298.390  Millions$ 97.605  Millions
Macrogenics Inc   3.03 $ 179.625  Millions$ 59.309  Millions
Verastem Inc   3.03 $ 113.175  Millions$ 37.374  Millions
Corcept Therapeutics Inc  3.01 $ 380.336  Millions$ 126.216  Millions
Immix Biopharma Inc   3.00 $ 19.690  Millions$ 6.565  Millions
Bolt Biotherapeutics Inc   2.98 $ 53.798  Millions$ 18.083  Millions

Date modified: 2026-08-29T17:19:29+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.